Regeneron Pharmaceuticals Files 8-K
Ticker: REGN · Form: 8-K · Filed: Jul 8, 2024 · CIK: 872589
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. (REGN) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $24 million, $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations-update
Related Tickers: REGN
TL;DR
REGN filed an 8-K on July 8th for financial updates.
AI Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on July 8, 2024, to report results of operations and financial condition. The filing does not contain specific financial figures or operational details in the provided text, but serves as a notification of these updates.
Why It Matters
This filing indicates that Regeneron Pharmaceuticals is providing an update on its financial performance and operational status to the SEC and its investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural document and does not contain information that inherently increases risk.
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Registrant
- July 8, 2024 (date) — Date of Report
- New York (location) — State of Incorporation
- 777 Old Saw Mill River Road (address) — Principal Executive Offices
- Tarrytown (location) — City of Principal Executive Offices
- 10591-6707 (zip_code) — Zip Code of Principal Executive Offices
- 914-847-7000 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this Form 8-K filing by Regeneron Pharmaceuticals, Inc.?
The purpose of this Form 8-K filing is to report on the Results of Operations and Financial Condition of Regeneron Pharmaceuticals, Inc.
On what date was this Form 8-K filed?
This Form 8-K was filed on July 8, 2024.
What is the principal executive office address for Regeneron Pharmaceuticals, Inc.?
The principal executive office address is 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.
What is the telephone number for Regeneron Pharmaceuticals, Inc.?
The telephone number for Regeneron Pharmaceuticals, Inc. is (914) 847-7000.
In which state was Regeneron Pharmaceuticals, Inc. incorporated?
Regeneron Pharmaceuticals, Inc. was incorporated in New York.
Filing Stats: 1,045 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2024-07-08 07:00:30
Key Financial Figures
- $0.001 — h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M
- $24 million — ent (" IPR&D ") charge of approximately $24 million on a pre-tax basis. This charge relates
- $0.18 — he second quarter 2024 by approximately $0.18. Acquired IPR&D charges may include IP
Filing Documents
- tm2418837d1_8k.htm (8-K) — 28KB
- 0001104659-24-078172.txt ( ) — 198KB
- regn-20240708.xsd (EX-101.SCH) — 3KB
- regn-20240708_lab.xml (EX-101.LAB) — 33KB
- regn-20240708_pre.xml (EX-101.PRE) — 22KB
- tm2418837d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (" GAAP ") and its non-GAAP financial results for the second quarter 2024 will include an acquired in-process research and development (" IPR&D ") charge of approximately $24 million on a pre-tax basis. This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the second quarter 2024 by approximately $0.18. Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as up-front, opt-in, certain development milestone payments, and premiums paid on equity securities related to collaboration and licensing agreements. Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period. Regeneron's results for the second quarter 2024 have not been finalized and are subject to Regeneron's financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary (unaudited) estimates described herein. The information included in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Note Regarding Forward-Looking Statements This Current Report on Form 8-K (this "Report") includes forward-looking statements that involve risks and uncertainties relat
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REGENERON PHARMACEUTICALS, INC. /s/ Joseph J. LaRosa Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Date: July 8, 2024